Peptide conjugation at the 5′-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity

Bioconjugate Chemistry

Volumn 21, Issue 1, 2010, Pages 39-45

  Putta, Mallikarjuna Reddy ^a   Zhu, Fu Gang ^a   Wang, Daqing ^a   Bhagat, Lakshmi ^a   Dai, Meiru ^a   Kandimalla, Ekambar R ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; INTERLEUKIN 12; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DISULFIDE BOND; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PROTEIN EXPRESSION; SPLEEN CELL;

BACTERIA (MICROORGANISMS); MUS;

EID: 74949085031     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900425s     Document Type: Article

References (37)

1. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
2. Yamamoto, S., Yamamoto, T., Nojima, Y., Umemori, K., Phalen, S., McMurray, D. N., Kuramoto, E., Iho, S., Takauji, R., Sato, Y., Yamada, T., Ohara, N., Matsumoto, S., Goto, Y., Matsuo, K., and Tokunaga, T. (2002) Discovery of immunostimulatory CpG-DNA and its applications to tuberculosis vaccine development. Jpn. J. Infect. Dis. 55, 37-44.
3. Agrawal, S., and Kandimalla, E. R. (2005) Role of Toll-like receptors in antisense and siRNA. Nat. Biotechnol. 22, 1533-1537.
4. O'Neill, L. A., Bryant, C. E., and Doyle, S. L. (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61, 177-197.
5. Klinman, D. M., Currie, D., Gursel, I., and Verthelyi, D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216.
6. McCluskie, M. J., and Davis, H. L. (1998) CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161, 4463-4466.
7. Oxenius, A., Martinic, M. M. A., Hengartner, H., and Klenerman, P. (1999) CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J. Virol. 73, 4120-4126.
8. Schneeberger, A., Wagner, C., Zemann, A., Luhrs, P., Kutil, R., Goos, M., Stingl, G., and Wagner, S. N. (2004) CpG motifs are efficient adjuvants for DNA cancer vaccines. J. Investig. Dermatol. 123, 371-379.
9. Zhu, F. G., Kandimalla, E. R., Yu, D., and Agrawal, S. (2007) Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J. Allergy Clin. Immunol. 120, 631-637.
10. Aurisicchio, L., Peruzzi, D., Conforti, A., Dharmapuri, S., Biondo, A., Giampaoli, S., Fridman, A., Bagchi, A., Winkelmann, C. T., Gibson, R., Kandimalla, E. R., Agrawal, S., Ciliberto, G., and La Monica, N. (2009) Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin. Cancer Res. 15, 1575-1584.
11. Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., Laframboise, C., Al Adhami, M. J., Khaliq, Y., Seguin, I., and Cameron, D. W. (2004) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix infleuenza vaccine. Vaccine 22, 3136-3143.
12. Halperin, S. A., Dobson, S., McNeil, S., Langley, J. M., Smith, B., McCall-Sani, R., Levitt, D., Van Nest, G., Gennevois, D., and Eiden, J. J. (2006) Comparison of the safety and immunogenicity of hepatitis B virus surgace antigen co-administered with an immunostimulatory phosphorothioate oligonculetide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24, 20-26.
13. Krishnamachari, Y., and Salem, A. K. (2009) Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv. Drug Delivery Rev. 61, 205-217.
14. Tighe, H., Takabayashi, K., Schwartz, D., Marsden, R., Beck, L., Corbeil, J., Richman, D. D., Eiden, J. J., Spiegelberg, H. L., and Raz, E. (2000) Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30, 1939-1947.
15. Tighe, H., Takabayashi, K., Schwartz, D., Van Nest, G., Tuck, S., Eiden, J. J., Kagey-Sobotka, A., Creticos, P. S., Lichtenstein, L. M., Spiegelberg, H. L., and Raz, E. (2000) Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124-134.
16. Heit, A., Maurer, T., Hochrein, H., Bauer, S., Huster, K. M., Busch, D. H., and Wagner, H. (2003) Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170, 2802-2805.
17. Daftarian, P., Sharan, R., Haqa, W., Ali, S., Longmate, J., Termini, J., and Diamonda, D. J. (2005) Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23, 3453-3468.
18. Agrawal, S., Christodoulou, C., and Gait, M. J. (1986) Efficient methods for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides. Nucleic Acids Res. 14, 6227-6245.
19. Zhao, Q., Yu, D., and Agrawal, S. (1999) Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg. Med. Chem. Lett. 9, 3453-3458.
20. Zhao, Q., Yu, D., and Agrawal, S. (2000) Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg. Med. Chem. Lett. 10, 1051-1054.
21. Yu, D., Kandimalla, E. R., Zhao, Q., Cong, Y., and Agrawal, S. (2002) Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages. Nucleic Acids Res. 30, 1613-1619.
22. Agrawal, S., and Kandimalla, E. R. (2001) Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 197-209.
23. Yu, D., Kandimalla, E. R., Zhao, Q., Cong, Y., and Agrawal, S. (2001) Immunostimulatory activity of CpG oligonucleotides containing nonionic methylphosphonate linkages. Bioorg. Med. Chem. 9, 2803-2808.
24. Yu, D., Kandimalla, E. R., Zhao, Q., Cong, Y., and Agrawal, S. (2001) Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg. Med. Chem. Lett. 11, 2263-2267.
25. Yu, D., Kandimalla, E. R., Zhao, Q., Bhagat, L., Cong, Y., and Agrawal, S. (2003) Requirement of nucleotide bases proximal to a CpG-motif for immunostimulatory activity of synthetic oligonucleotides. Bioorg. Med. Chem. 11, 459-464.
26. Yu, D., Kandimalla, E. R., Cong, Y., Tang, J., Tang, J. Y., Zhao, Q., and Agrawal, S. (2002) Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J. Med. Chem. 45, 4540-4548.
27. Yu, D., Zhao, Q., Kandimalla, E. R., and Agrawal, S. (2000) Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg. Med. Chem. Lett. 10, 2585-2588.
28. Kandimalla, E. R., Bhagat, L., Yu, D., Cong, Y., Tang, J., and Agrawal, S. (2002) Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjugate Chem. 13, 966-974.
29. Iyer, R. P., Egan, W., Regan, J. B., and Beaucage, S. L. (1990) 3H-1,2-Benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112, 1253-1254.
30. 1-MedG modifications. Nucleic Acids Res. 34, 3231-3238.
31. Kandimalla, E. R., Bhagat, L., Wang, D., Yu, D., Zhu, F. G., Tang, J., Wang, H., Huang, P., Zhang, R., and Agrawal, S. (2003) Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 31, 2393-2400.
32. Stacey, K. J., Sweet, M. J., and Hume, D. A. (1996) Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157, 2116-2122.
33. Creticos, P. S., Schroeder, J. T., Hamilton, R. G., Balcer-Whaley, S. L., Khattignavong, A. P., Lindblad, R., Li, H., Coffman, R., Seyfert, V., Eiden, J. J., and Broide, D. (2006) Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355, 1445-1455.
34. Broide, D. H. (2005) Immunostimulatory sequences of DNA and conjugates in the treatment of allergic rhinitis. Curr. Allergy Asthma Rep. 5, 182-185.
35. Heit, A., Huster, K. M., Schmitz, F., Schiemann, M., Busch, D. H., and Wagner, H. (2004) CpG-DNA aided cross-priming by cross-presenting B cells. J. Immunol. 172, 1501-1507.
36. Heit, A., Schmitz, F., O'Keeffe, M., Staib, C., Busch, D. H., Wagner, H., and Huster, K. M. (2005) Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174, 4373-4380.
37. Suzuki, M., Ohta, N., Min, W. P., Matsumoto, T., Min, R., Zhang, X., Toida, K., and Murakami, S. (2007) Immunotherapy with CpG DNA conjugated with T-cell epitope peptide of an allergenic Cry j 2 protein is useful for control of allergic conditions in mice. Int. Immunopharmacol. 7, 46-54.